Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ibnsina Pharma's Accounts Payable for the quarter that ended in Mar. 2026 was E£27,940 Mil.
Ibnsina Pharma's quarterly Accounts Payable
increased
from Sep. 2025 (E£23,704 Mil) to Dec. 2025 (E£25,476 Mil) and
increased
from Dec. 2025 (E£25,476 Mil) to Mar. 2026 (E£27,940 Mil).
Ibnsina Pharma's annual Accounts Payable
increased
from Dec. 2023 (E£11,858 Mil) to Dec. 2024 (E£19,921 Mil) and
increased
from Dec. 2024 (E£19,921 Mil) to Dec. 2025 (E£25,476 Mil).
The historical data trend for Ibnsina Pharma's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
What does a Accounts Payable of E£27,940 Mil mean?
Ibnsina Pharma (CAI:ISPH) has a Accounts Payable of E£27,940 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Ibnsina Pharma and its competitors.
Is Ibnsina Pharma's Accounts Payable too high?
Ibnsina Pharma's current Accounts Payable is E£27,940 Mil. Overall, Ibnsina Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Accounts Payable compare to MCK and COR?
Ibnsina Pharma's Accounts Payable of E£27,940 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Distribution company?
A good Accounts Payable depends on the Medical Distribution industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Ibnsina Pharma and its competitors. Ibnsina Pharma's current Accounts Payable is E£27,940 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.76, compared to a current price of E£13.60 — trading 26.4% above its estimated fair value. The current Accounts Payable is E£27,940 Mil. Ibnsina Pharma's overall GF Score™ is 86/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Accounts Payable is E£27,940 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£13.60 is trading 26.4% above its estimated GF Value™ of E£10.76.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
Accounts Payable: E£27,940 Mil
GF Value™: E£10.76 vs. price of E£13.60 (26.4% above fair value)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
86GF Score
Get the complete analysis for CAI:ISPH
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
